5-Amino-1MQ vs AOD-9604
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: NNMT inhibition and NAD+ metabolism research in preclinical models vs. Research requiring human safety data or GH-fragment lipolysis mechanisms, with the caveat that Phase.
Quick Answers
Which is better, 5-Amino-1MQ or AOD-9604?
Neither compound has a universal evidence advantage. Research distinction: NNMT inhibition and NAD+ metabolism research in preclinical models vs. Research requiring human safety data or GH-fragment lipolysis mechanisms, with the caveat that Phase.
What is the key difference between 5-Amino-1MQ and AOD-9604?
AOD-9604 is a modified fragment of human growth hormone (hGH176-191) targeting lipolysis; 5-Amino-1MQ is a small-molecule NNMT inhibitor targeting cellular energy metabolism - different compound classes entirely.
Evidence Comparison
AOD-9604: completed Phase 3 obesity trials but failed to show significant weight loss vs. placebo; subsequently received GRAS status as a food ingredient. 5-Amino-1MQ: mouse studies only from a single lab. AOD-9604 has more human safety data despite its efficacy failure; neither has demonstrated human efficacy.
Evidence Context Favoring 5-Amino-1MQ
NNMT inhibition and NAD+ metabolism research in preclinical models.
Evidence Context Favoring AOD-9604
Research requiring human safety data or GH-fragment lipolysis mechanisms, with the caveat that Phase 3 efficacy was negative.
Side-by-Side Snapshot
| Evidence grade | 5-Amino-1MQ: Level D AOD-9604: Level D |
|---|---|
| Research status | 5-Amino-1MQ: Preclinical AOD-9604: Preclinical |
| Primary category | 5-Amino-1MQ: Weight Loss & Metabolic AOD-9604: Weight Loss & Metabolic |
| Cited studies | 5-Amino-1MQ: 2 AOD-9604: 2 |